

Dr. Benjamin Hayes Bibliography

Effectiveness of Buprenorphine:

1. Laroche MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. *Ann Intern Med*. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19. PMID: 29913516; PMCID: PMC6387681.
2. Heikkinen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, Lähteenvuo M, Tiihonen J. Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort. *Addiction*. 2022 Jun;117(6):1683-1691. doi: 10.1111/add.15814. Epub 2022 Feb 7. PMID: 35072314; PMCID: PMC9305765.

Safer Injection Facilities in the Literature:

1. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet*. 2011 Apr 23;377(9775):1429-37. doi: 10.1016/S0140-6736(10)62353-7. Epub 2011 Apr 15. PMID: 21497898.
2. Chalfin A, del Pozo B, Mitre-Becerril D. Overdose Prevention Centers, Crime, and Disorder in New York City. *JAMA Netw Open*. 2023;6(11):e2342228. Doi:10.1001/jamanetworkopen.2023.42228
3. Harocopos A, Gibson BE, Saha N, et al. First 2 Months of Operation at First Publicly Recognized Overdose Prevention Centers in US. *JAMA Netw Open*. 2022;5(7):e2222149. doi:10.1001/jamanetworkopen.2022.22149
4. Kimber J, Mattick RP, Kaldor J, van Beek I, Gilmour S, Rance JA. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. *Drug Alcohol Rev*. 2008 Nov;27(6):602-12. doi: 10.1080/09595230801995668. PMID: 19378444.
5. Salmon AM, Thein HH, Kimber J, Kaldor JM, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? *Int J Drug Policy*. 2007 Jan;18(1):46-53. doi: 10.1016/j.drugpo.2006.11.010. Epub 2007 Jan 8. PMID: 17689343.

Dr. Benjamin Hayes in the Literature:

1. Hayes, B. T., Sanchez Fat, G., Torres-Lockhart, K., Khalid, L., Minami, H., Ghiroli, M., Hribar, M. B., Pacifico, J., Bao, Y., Rodgers, C. R. R., Gabbay, V., Starrels, J., & Fox, A. D. (2025). Low-Dose Buprenorphine Initiation for Hospitalized Patients With Chronic Pain and Opioid Use Disorder or Opioid Misuse: Protocol for an Open-Label, Parallel-Group, Effectiveness-Implementation Randomized Controlled Trial. *Substance Use and Addiction Journal*, 46(1), 184-191. <https://doi.org/10.1177/29767342241263221>
2. Jakubowski, A., Norton, B. L., Hayes, B. T., Gibson, B. E., Fitzsimmons, C., Stern, L. S., Ramirez, F., Guzman, M., Spratt, S., Marcus, P., & Fox, A. D. (2022). Low-threshold

Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. *Journal of addiction medicine*, 16(4), 447-453.

<https://doi.org/10.1097/ADM.0000000000000934>

3. Slawek, D. E., Lu, T. Y., Hayes, B., & Fox, A. D. (2019). Caring for patients with opioid use disorder: What clinicians should know about comorbid medical conditions.

Psychiatric Research and Clinical Practice, 1(1), 16-26.

<https://doi.org/10.1176/appi.prcp.20180005>

21 U.S.C. § 856--The Crack House Statute:

<https://www.govinfo.gov/content/pkg/USCODE-2024-title21/pdf/USCODE-2024-title21-chap13-subchapl-partD-sec856.pdf>